Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL
05:24am, Monday, 19'th Jan 2026
SG Americas Securities LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 215.6% during the third quarter, according to its most recent filing with the SEC. The firm o
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
08:00am, Thursday, 15'th Jan 2026
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD prod
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025
05:03am, Wednesday, 14'th Jan 2026
On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares directly through an exercise of options. The sale represented 14.5% of Dreyer'
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
10:40am, Monday, 12'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium Provides 2026 Financial Guidance and Business Update
08:00am, Thursday, 08'th Jan 2026
– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
08:00am, Tuesday, 30'th Dec 2025
STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.
Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month High – Here’s What Happened
02:55am, Sunday, 28'th Dec 2025
Shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) reached a new 52-week high on Friday. The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
10:41am, Monday, 22'nd Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Assenagon Asset Management S.A. Purchases 92,898 Shares of Collegium Pharmaceutical, Inc. $COLL
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 90.5% during the third quarter, according to its most recent filing with the SEC. The
Best Value Stocks to Buy for Dec. 18
06:15am, Thursday, 18'th Dec 2025
KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
10:41am, Thursday, 04'th Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?
10:16am, Thursday, 04'th Dec 2025
Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Peak Advisors Inc Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL
04:46am, Monday, 01'st Dec 2025
Ensign Peak Advisors Inc cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to the company in its most recent disclosure with the
Ballast Asset Management LP Makes New Investment in Collegium Pharmaceutical, Inc. $COLL
03:26am, Monday, 01'st Dec 2025
Ballast Asset Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Advantage Alpha Capital Partners LP
04:16am, Friday, 28'th Nov 2025
Advantage Alpha Capital Partners LP decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to its most recent disclosure with the Securities
